There is growing concern regarding the clinical relevance of therapy testing in immortalized cell lines and animal models. The advent of induced pluripotent stem cells allows conduction of early diagnostics and potential therapy testing in cell derived from a specific patient retaining his/her genetic background. This is especially important in studies of various heritable cardiomyopathies, which are difficult to recapitulate in animal models. A number of methods have been developed building upon the pioneering work of Yamanaka laboratory, aiming at reprogramming various somatic cells to cardiomyocytes and creating two- and three-dimensional models for investigation of cardiac physiology in a particular genetic background. Conventional models, such as short-lived primary cell preparations, monolayer cell cultures, coronary-perfused hearts and preparations, and, more recently, heart slices have unique advantages and limitations, especially in studies of long-term chronic conditions. The emerging induced pluripotent stem-cell-derived cardiomyocyte (iPSC-CM) platform holds significant potential to overcome these limitations while allowing patient-specific diagnostics and therapy development. This chapter compares conventional models with iPSC-CM, reviews cardiogenesis as the basis for reprogramming protocol development, focuses on the iPSC-CM disease modeling platforms for drug testing and patient specific thera-nostics, and concludes with clinical studies on transplantation of in vitro derived CMs.
|Original language||English (US)|
|Title of host publication||Stem Cells - From Hype to Real Hope|
|Number of pages||19|
|State||Published - Dec 17 2018|
- Drug discovery
ASJC Scopus subject areas
- Biochemistry, Genetics and Molecular Biology(all)